Which generation of drug is Brigatinib? How effective is it? How much does a box cost now?

Brigatinib (also known as brigatinib), trade name Ambry , is a targeted therapy drug that has received widespread attention in recent years. It is classified as a second-generation ALK tyrosine kinase inhibitor and is particularly suitable for patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

In terms of efficacy, brigatinib shows better results than first-generation drugs. It can precisely act on ALK fusion-positive lung cancer cells and inhibit the growth and spread of tumors by effectively inhibiting the signaling pathways in these tumor cells. Clinical studies have shown that brigatinib can significantly prolong patients' survival and improve their quality of life.

In addition, brigatinib also showed good results in reducing tumor progression. It can slow down the progression of the disease to a certain extent and provide patients with more treatment time and survival chances. This comprehensive therapeutic effect makes brigatinib the first-choice treatment for many patients with ALK-positive NSCLC.

Regarding the price issue, as an imported drug, the price of brigatinib varies depending on the brand, specification and region. At present, the price of brigatinib’s original drug is still relatively high, which poses a certain financial burden to ordinary patients. However, it is gratifying that the drug has been covered by medical insurance, and patients can enjoy partial reimbursement. At the same time, generic drugs of brigatinib have also been launched one after another, and the price is relatively more affordable. For example, Lucius's version of brigatinib, with a specification of 90mg*30 tablets, is priced at about 1,000 yuan per box. When purchasing, patients should learn about the latest quotes through formal channels and make reasonable choices based on their own financial situation.

In general, brigatinib, as a second-generation ALK tyrosine kinase inhibitor, has outstanding efficacy and brings new treatment hope to patients with ALK-positive non-small cell lung cancer. Although the price factor still needs to be considered by patients, with the continuous changes in the market and policy support, it is believed that more and more patients will be able to benefit from the treatment of this innovative drug.